Despite some moderation, Q4 sales crossed expectations as healthy growth in Vaccines and HIV was overshadowed by declining sales of COVID-19 solutions. While 2023 is guided to be strong, COVID-19-related sales are expected to continue declining. Even as Vaccines and HIV continue their momentum, GSK needs to find other avenues for growth, preferably in high-potential oncology. Considering the firm’s legacy strengths and hope of an R&D turnaround, given the on-going initiatives, the share price of ....
07 Feb 2023
Q4 beat + strong guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 beat + strong guidance
GSK plc (GSK:LON) | 1,652 189.9 0.7% | Mkt Cap: 68,453m
- Published:
07 Feb 2023 -
Author:
Abhishek Raval -
Pages:
4
Despite some moderation, Q4 sales crossed expectations as healthy growth in Vaccines and HIV was overshadowed by declining sales of COVID-19 solutions. While 2023 is guided to be strong, COVID-19-related sales are expected to continue declining. Even as Vaccines and HIV continue their momentum, GSK needs to find other avenues for growth, preferably in high-potential oncology. Considering the firm’s legacy strengths and hope of an R&D turnaround, given the on-going initiatives, the share price of ....